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Abstract
Background: Long interspersed nuclear elements (LINEs), Alu and endogenous retroviruses
(ERVs) make up some 45% of human DNA. LINE-1 also called L1, is the most common family of
non-LTR retrotransposons in the human genome and comprises about 17% of the genome. L1
elements require the integration into chromosomal target sites using L1-encoded endonuclease
which creates staggering DNA breaks allowing the newly transposed L1 copies to integrate into
the genome. L1 expression and retrotransposition in cancer cells might cause transcriptional
deregulation, insertional mutations, DNA breaks, and an increased frequency of recombinations,
contributing to genome instability. There is however little evidence on the mechanism of L1-
induced genetic instability and its impact on cancer cell growth and proliferation.
Results: We report that L1 has genome-destabilizing effects indicated by an accumulation of γ-
H2AX foci, an early response to DNA strand breaks, in association with an abnormal cell cycle
progression through a G2/M accumulation and an induction of apoptosis in breast cancer cells. In
addition, we found that adjuvant L1 activation may lead to supra-additive killing when combined
with radiation by enhancing the radiation lethality through induction of apoptosis that we have
detected through Bax activation.
Conclusion: L1 retrotransposition is sensed as a DNA damaging event through the creation DNA
breaks involving L1-encoded endonuclease. The apparent synergistic interaction between L1
activation and radiation can further be utilized for targeted induction of cancer cell death. Thus, the
role of retrotransoposons in general, and of L1 in particular, in DNA damage and repair assumes
larger significance both for the understanding of mutagenicity and, potentially, for the control of
cell proliferation and apoptosis.
Background
Retrotransposons are mobile retroelements that utilize
reverse transcriptase and RNA intermediates to relocate
within the cellular genome. Retrotransposons are subdi-
vided into two subclasses: LTR-(long terminal repeats)
and non-LTR-retrotransposons. LINE-1 (Long Inter-
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spersed Nuclear Element type 1, or L1), is the most com-
mon family of non-LTR retrotransposons in the human
genome; with about 500,000 copies, it comprises about
17% of the genome [1,2]. Only a fraction of L1 elements
in the human genome are intact: most are truncated (usu-
ally at the 5' -end) and mutated (often at multiple sites).
However, there are still about 80–100 retrotransposition-
competent L1 elements (RC-L1s) in the genome. Most
RC-L1 sequences are evidently silenced by methylation [3]
and, possibly, also by the RNA interference pathway [4].
Genomic demethylation after deleting DNA methyltrans-
ferase 1 can trigger L1 elements to become mobilized [5].
L1 elements encode proteins necessary for their own
mobilization. L1 encodes a 40 kDa (p40) protein
(ORF1p) with RNA-binding activity [6], and ORF2p pro-
duces a 150 kDa protein with endonuclease [7] and
reverse transcriptase [8,9] activities. L1 integrates into the
genome by target-primed reverse transcription (TPRT)
using the free 3'-OH at the endonuclease cut site on the
genomic DNA as a primer and the L1 RNA as a template
[10]. ORF1p and ORF2p preferentially associate with their
encoding transcript to form a ribonucleoprotein particle
(RNP), which is a proposed retrotransposition intermedi-
ate.
Experimental strategy for assaying RC-L1 expression and retrotransposition Figure 1
Experimental strategy for assaying RC-L1 expression and retrotransposition. (A) L1 element consists of the 5'- and 
3'-UTRs and two ORFs. The EGFP retrotransposition cassette is cloned into the L1 3'-UTR in the antisense orientation. L1 ele-
ments tagged with the EGFP cassette are cloned into the pCEP4-based mammalian expression vector with puromycin resist-
ance gene. RC-L1-EGFP-expressing cells are sorted by FACS and retrotransposition is detected by EGFP fluorescence using 
fluorescence microscopy. (B) Confirmation of L1 retrotransposition by PCR as revealed by a 342 bp product. MCF-7 cells-
expressing L1-EGFP. Serial passaged cells (P1–P4) show the spliced form of EGFP at 342 bp. No DNA template used as nega-
tive control. L1-EGFP plasmid showing the unspliced form at 1243 bp used as a positive control. 1 Kb ladder used as a molecu-
lar weight marker.
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The retrotransposition of L1 elements requires the integra-
tion into chromosomal target sites using L1-encoded
endonuclease [7]. L1 endonuclease creates staggering
DNA breaks allowing the newly transposed L1 copies to
integrate into the genome. Despite the small number of
RC-L1s, and the constraints placed upon their movement
by cis-preference [11], characterization of retrotransposi-
tion events using tagged RC-L1 clones in cultured cells
indicate that about 10% of L1 insertions are accompanied
by large chromosomal rearrangements, suggesting that
active L1s could also lead to genomic instability [12,13].
While the properties of L1-encoded enzymes have been
studied extensively in vitro [10], the biological impact of
retroelements on normal and cancer cells requires clarifi-
cation and has been difficult to assess. We propose to test
the ability of RC-L1 to induce targeted DNA strand breaks
as a mechanism for inducing apoptosis in human cancer
cells. Although several reports exist that L1 induces
genomic instability, a precise mechanism of action and
especially its impact on cell growth is still generally lack-
ing. It is essential that a clear mechanistic model needs to
be established to provide a clear understanding of how
human L1 retrotransposition is sensed as a DNA damag-
ing event. Here we report that L1 has genome-destabiliz-
ing effects indicated by an accumulation of γ-H2AX foci,
an early response to DNA strand breaks, in association
with induction of apoptosis in breast cancer cells.
RC-L1 is expressed in breast cancer cells Figure 2
RC-L1 is expressed in breast cancer cells. RC-L1- expression determined by immunofluorescence using anti-L1 ORF1 (A) 
and anti-L1 ORF2 (B) rabbit polyclonal antibodies showed cytoplasmic "C" and nucleolar "N" staining. No specific staining was 
detected when using pre-immune serums as control. Immunoblotting of whole cell lysates using anti-ORF1 (C) or anti-ORF2 
(D) detected a 40 kD and a 150 kDa respectively. Additional bands were detected by anti-ORF2 antibody at 135 kDa and 66 
kDa which may be due to cleavage by a cellular protease. P1 through P4 correspond to consecutive passages of RC-L1 
expressing cells. Anti-α-tubulin was used as a loading control. Mock transfected cells serve as a negative control.
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Results
RC-L1 expression and retrotransposition assay
To monitor EGFP-tagged RC-L1 expression and retrotrans-
position, we have used a retrotransposition assay that has
previously been shown to efficiently detect and monitor
L1 retrotransposition events in different cell lines [16-18].
To test whether breast cancer cells can allow RC-L1 expres-
sion and retrotransposition, MCF-7 cells were stably trans-
fected with a human RC-L1 tagged with an EGFP antisense
cassette, which is interrupted by a γ-globin intron allow-
ing L1 retrotransposition only after splicing of the intron
[17] (Fig. 1). The detection of cells expressing EGFP is
indicative of delivery, expression and retrotransposition
of RC-L1 in these cells (Fig. 1). In order to confirm that
resistant clones generated after selection harbor an
"active" spliced form of RC-L1, we performed a PCR anal-
ysis to verify whether the γ-globin intron has been
removed by splicing during L1 retrotransposition events.
New retrotransposition events were detected by the pres-
ence of the spliced form of EGFP with 342 bp size.
RC-L1 ORFs are expressed in MCF-7 cells
To check whether EGFP-expressing cells harboring RC-L1
were expressing the L1 proteins necessary for retrotrans-
position, we investigated the presence of both L1-ORF1
and L1-ORF2 products by immunostaining (Fig. 2a and
Cell cycle and DNA damage response analysis of RC-L1-expressing cells Figure 3
Cell cycle and DNA damage response analysis of RC-L1-expressing cells. MCF-7 cells either Mock transfected, 
expressing GFP or RC-L1 were analyzed by FACS as described under "Experimental Procedures". The histograms represent 
the distribution of cells through the cell cycle measured by flow cytometry and analyzed with ModFit. (A) untransfected MCF-
7 cells. (B) MCF-7 cells transfected with EGFP (C) MCF-7 cells transfected with RC-L1. The percentage of cells in G2 or M is 
shown for each treatment group. Detection of the induction of γ-H2AX foci formation using anti-γ-H2AX polyclonal antibody. 
(D) by immunostaining of Mock transfected cells and serially passaged RC-L1-expressing cells (P1-P4) (E) Number of γ-H2AX 
foci in four different cell passages, P1-P4. Error bars show s.d. (F). Expression level of γ-H2AX determined by immunoblotting.
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2b) and by immunoblotting (Fig. 2c and 2d) using anti-
ORF1 and anti-ORF2 rabbit polyclonal antibodies. ORF1
and ORF2 proteins were detected in RC-L1-expressing
MCF-7 cells mainly in the cytoplasm and in nucleolar sites
consistent with previous reports [9].
RC-L1 expressing cells exhibit an abnormal cell cycle 
progression and a DNA damage recognition response
In order to check whether RC-L1 expression and retro-
transposition impacts on cell cycle progression, MCF-7
cells were tested for cell cycle profile and DNA damage
response following RC-L1 expression and retrotransposi-
tion. We analyzed the cell cycle status in the presence of
either GFP (control) or RC-L1 in MCF-7 cells. The percent-
age of cells accumulating in 4N following RC-L1 expres-
sion was ~5-fold over non-transfected cells (Fig. 3A–C)
while cells transfected with GFP show no significant
increase in 4N when compared with non-tranfected cells.
An early response to DSBs is phosphorylation of H2AX, a
variant form of the histone H2AX. Phosphorylated H2AX,
termed γ-H2AX, can be observed over several megabases
flanking the DSB [19]. The role of H2AX and the proteins
that accumulate at the site of DSBs is promoting survival
of the cells [20]. The presence of γ-H2AX provides the plat-
form for other damage proteins such as 53BP1, Mre11
and Brac1 to localize to the break site [21]. To determine
whether RC-L1 expression and retrotransposition is
sensed as a DNA damaging event, we checked for the acti-
vation and accumulation of γ-H2AX in discrete sites
known as DNA damage repair foci. The histone γ-H2AX is
rapidly phosphorylated at the sites of DNA double-strand
Induction of apoptosis in breast cancer cells harboring RC-L1 Figure 4
Induction of apoptosis in breast cancer cells harboring RC-L1. (A) Pro-apoptotic bax gene expression level deter-
mined by immunoblotting using anti-Bax polyclonal antibody. Anti-α-tubulin was used as a loading control. Mock transfected 
cells serve as a negative control. (B). Induction of apoptosis in RC-L1-expressing cells determined using caspase 3 assay.
0
2
4
6
8
10
Mock P1 P 2 P3 P 4
C
a
s
p
a
s
e
 
3
-
A
c
t
i
v
i
t
y
 
(
F
o
l
d
 
I
n
c
r
e
a
s
e
)
B
Bax
D-Tubulin
Mock
P1
P2
P3
P4
ACancer Cell International 2006, 6:13 http://www.cancerci.com/content/6/1/13
Page 6 of 10
(page number not for citation purposes)
breaks (DSBs) [19]. Interestingly, γ-H2AX is activated and
appears as discrete nuclear foci in RC-L1-expressing cells,
suggesting that integration had induced such breaks in
DNA (Fig. 3D–F).
Induction of apoptosis in RC-L1-expressing cells
Since induction of apoptosis is an early response to DNA
damage, we examined to what extent it is induced in MCF-
7 cells expressing RC-L1. Expression of a pro-apoptotic
gene was analyzed by immunoblotting using anti-Bax
antibody. Bax expression was induced in RC-L1-express-
ing cells passaged for up to 4 consecutives passages (P1-
P4), but declined with passage number (Fig. 4A). Apopto-
sis induction in MCF-7 cells expressing RC-L1 was also
tested using a caspase 3 assay. Caspase 3 is an active cell-
death protease involved in the execution phase of apopto-
sis. There was a seven-fold increase in expression of this
marker of apoptosis in comparison with mock-transfected
cells (Fig. 4B). The level of expression diminished with
additional cell passages. These data corresponded closely
to the levels of DNA damage observed using the γ-H2AX
foci assay, and they demonstrated that induction of apop-
tosis is associated with the presence of a retrotransposi-
tion-competent L1 in MCF-7 cells.
Impact of RC-L1 expression and retrotransposition on p53 mutant cells Figure 5
Impact of RC-L1 expression and retrotransposition on p53 mutant cells. (A) Confirmation of L1 retrotransposition 
by PCR as revealed by a 342 bp product. (B) The histograms represent the distribution of cells through the cell cycle measured 
by flow cytometry and analyzed with ModFit. "A" untransfected T47D cells. "B" T47D cells transfected with EGFP "C" T47D 
cells transfected with RC-L1. (C) RC-L1- expression determined by immunofluorescence using anti-L1 ORF1 and anti-L1 ORF2 
rabbit polyclonal antibodies (upper panels). Detection of the induction of γ-H2AX nuclear foci formation using anti-γ-H2AX 
polyclonal antibody (lower panels). (D) Pro-apoptotic bax gene expression level determined by immunoblotting using anti-Bax 
polyclonal antibody in T47D cells either expressing RC-L1, or treated with 5Gy radiation or both and assessed at the indicated 
time points.
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RC-L1 retrotransposition in p53 mutant cells
We have previously shown that the impact of L1 expres-
sion and retrotransposition on the target cell is dependent
upon the p53 status [14]. To further clarify whether p53
mutant cells will sense L1 expression and retrotransposi-
tion through the same mechanism as p53 wild type cells,
we expressed RC-L1 in T47D breast cancer p53 mutant
cells. We first checked for correct splicing of EGFP-L1 con-
struct (figure 5A), then asked whether RC-L1 will have any
impact the cell cycle profile. We found that in T47D with
mutant p53, RC-L1 does not seem to significantly alter
cell cycle progression in these cells (figure 5B). To ensure
that RC-L1 is appropriately expressed in these cells, we
performed an immunobloting analysis of T47D cells
transfected with RC-L1 and probed with anti-L1 ORF1 or
anti-L1 ORF2 antibodies. We were indeed able to detect
ORF1 and ORF2 proteins mainly in the cytoplasm of these
cells with occasionally some staining in the nucleolus, in
particular with anti-L1 ORF2 antibody.
We then checked for RC-L1 ability to activate H2AX in
these cells. We did not detect any significant activation of
H2AX after RC-L1 expression and retrotransposition in
comparison with the level of H2AX activation in MCF-7
cells expressing RC-L1 (figure 5, panel C).
Since T47D cells do not seem to allow similar RC-L1 ret-
rotransposition level as MCF-7 cells with wild type p53,
we then postulated that simultaneously inducing DSBs via
γ-irradiation and L1 activation will possibly swamp the
capacity of DNA repair pathways to process Radiation
Induced DSBs (RIDSBs). We further postulated that
RIDSBs and L1-induced DSBs will competitively sequester
γH2AX (and the associated repair protein complexes),
resulting in sub-optimal levels of the "repairsome" at each
loci; which will delay the processing of the DSBs. In the
case of RIDSBs this increased persistence may result in an
increased conversion to chromosomal aberrations or may
trigger apoptotic cell death. Thus the co-administration of
RC-L1 may be a powerful adjuvant to radiation in tumors
that are inherently resistant to radiation. Alternatively, the
additional sequestration of γ-H2AX/NHEJ complex by
RIDSBs may serve to enhance the L1-mediated signal for
apoptosis. Our results showed that indeed RC-L1
enhances the radiation-induced apoptosis as measured by
immunoblotting using anti-Bax antibody (figure 5, panel
D).
Discussion
Insertion of an L1 copy into the genome necessitates the
creation and repair of broken DNA. After L1 integration,
the DNA ends are sealed and filled in, forming the target
site duplications that flank a typical L1 insertion. Reacti-
vation of L1 retrotransposition may interfere with poten-
tial *symbiotic' effects of L1 sequences such as their
contribution to the global and local organization of the
genome and the provision of gene regulatory sequences.
Increased L1 retrotransposition may instead have a delete-
rious effect on the cell. It is widely presumed that L1 inte-
gration is random, therefore, increasing its mobility will
most likely have neutral or negative consequences for the
host cell. Even simply upregulating the L1 endonuclease
in the absence of successful integration could be toxic to
the cell by promoting the formation of additional DSBs,
fostering chromosomal rearrangements and transloca-
tions. Furthermore, following DNA damage, cells initiate
a repair response, which depends upon the close coordi-
nation of cell cycle checkpoints and activated DNA repair
[22]. If the repair does not occur in a timely fashion or if
the damage is massive, cell death by mechanisms involv-
ing apoptosis can occur [23,24].
L1-encoded endonuclease creates staggered DNA breaks,
which enables newly-transposed L1 copies to integrate
into the genome [7]. The outcome of single-strand breaks
introduced by the endonuclease in a cell depends on sev-
eral factors. A first factor is the cell cycle phase. Nicks in S-
phase are most problematic, because they can be con-
verted into double-strand breaks by the replication com-
plex. A second factor is the DNA repair competency and
capacity of the cell which may differ between normal and
cancer cells. Thirdly, the presence of L1 RNA and other
proteins at the nicked site may influence the type and effi-
ciency of repair.
In a recent study, Goodier et al., have mapped a functional
nucleolar localization signal in L1 ORF2. They showed
that L1 ORF1 is localized in the cytoplasm with a speckled
pattern and colocalized with ORF2 in nucleoli in a subset
of cells [9]. However, although wild-type ORF2 expres-
sion was repeatedly observed, detectable levels remained
prohibitively low. One cause of poor detection could be
cell toxicity induced by nicking of genomic DNA by the
endonuclease [9]. Similarly, early events in retroviral rep-
lication include entry of the viral capsid with the accom-
panying enzymes reverse transcriptase and integrase (IN)
followed by synthesis of a DNA copy of the viral RNA
genome to form a preintegration complex. This complex
then enters the nucleus, and integration is first detected at
approximately 3–4 h postinfection [25]. Retroviral inte-
gration is catalyzed by integrase acting on specific
sequences at the ends of the viral DNA and via a concerted
cleavage-ligation reaction that is mechanistically similar
to that catalyzed by RAG proteins during V(D)J recombi-
nation [26,27]. As a consequence of integrase-mediated
joining, the host cell DNA suffers a DSB, but the ends are
held together by single strand links to viral DNA. Postin-
tegration repair of this intermediate is essential for the
maintenance of host DNA integrity as well as the stable
association of retroviral DNA with host chromosomes.Cancer Cell International 2006, 6:13 http://www.cancerci.com/content/6/1/13
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Numerous lines of evidence [28-30] indicate that retrovi-
ral DNA elicits a DNA damage response and that the inte-
gration intermediate is repaired primarily viacomponents
of the non-homologous end-joining (NHEJ) pathway. It
is noteworthy that Daniel et al., [31] provided direct con-
firmation that cultured cells respond to retroviral DNA
integration in the same way that they respond to DSBs
produced by a variety of genotoxic agents or normal pro-
grammed events, namely, by massive phosphorylation of
histone H2AX in the vicinity of the damage site. The sec-
ond finding is that H2AX appears to be dispensable for
postintegration repair. These observations lend independ-
ent support to a model in which the anchoring of broken
DNA ends to facilitate their repair is a critical function of
γ-H2AX [31]. Severe DNA damage can result in cell cycle
arrest and apoptosis [32]. Both cell cycle arrest and apop-
tosis have been seen to accompany retrotransposition in
severely stressed cells [33].
Conclusion
This is the first demonstration that human L1 retrotrans-
position induces DNA damage, as indicated by γ-H2AX
accumulation. It also reveals a correlation between L1
expression/retrotransposition and induction of apoptosis.
Taken together, the data imply that DNA nicks created by
RC-L1 expression and retrotransposition are sensed as a
DNA damaging event, which leads to apoptosis in cancer
cells. Obviously further studies are needed to test whether
additional components in the DNA damage recognition
response, in particular NMR complex (Nbs1, MRE11,
Rad50) and/or ATM are involved in signaling RC-L1 retro-
transposition effects on these cells. In addition, while we
realize that it is most likely the impact of the "active" form
of L1, or RC-L1 that induces this DNA damage response,
it will be of interest to clarify whether it is because of DNA
double strand breaks or other intermediates in the retro-
transposition cycle. While this manuscript was under
review two other independent reports have been pub-
lished by two different groups leading to the same conclu-
sion indicating the activation of γ-H2AX in response to L1
expression and retrotransposition through the creation of
DNA double strand breaks [34,35]
Methods
Cells, plasmids, and antibodies
MCF-7 and T47D human carcinoma cells were grown in
DMEM (Gibco-BRL) supplemented with 10% fetal calf
serum and 1% penicillin-streptomycin. L1-EGFP con-
struct was obtained from E. Luning Prak (University of
Pennsylvania, PA, USA). The anti-L1 ORF1 rabbit polyclo-
nal antibody was a gift from Gerald Schumann (Paul-Ehr-
lich-Institut, Langen, Germany). The anti-L1-ORF2 rabbit
polyclonal antibody was a gift from John Goodier (Uni-
versity of Pennsylvania, PA, USA). Anti-α-tubulin mouse
monoclonal antibody from Sigma. Anti-γ-H2AX rabbit
polyclonal antibody from Cell Signaling Technologies
and FITC-conjugated secondary antibody from ICN Bio-
medicals, Inc.
Cell transfection and selection
Cells were seeded in 6-well plates with about 4 × 105 cells/
well and grown to 70% confluency in DMEM complete
medium. Cells were transfected with the L1-EGFP con-
struct using Lipofectamin 2000 transfection reagent (Inv-
itrogen) following the manufacturer's protocol. Each
transfection well received 2 µg plasmid DNA, 6 µl trans-
fection reagent and 2 ml DMEM complete medium. Anti-
biotic selection was begun 24 h after transfection.
Puromycin-resistant cells (purR) were selected by growth
in DMEM complete medium containing 10 µg/ml puro-
mycin.
Isolation of genomic DNA and PCR analysis
Genomic DNA was isolated using Qiagen Blood & Cell
Culture DNA Mini Kit Kit following the manufacturer's
protocol. The oligonucleotides used for PCR were
GFP968F (5' GCACCATCTTCTTCAAGGACGAC-3') and
GFP1013R (5'-TCTTTGCTCAGGGCGGACTG-3'). Ampli-
fications were performed in 50 µl containing 1.25 U
AmpliTaq Gold polymerase (Roche), 2.5 mM MgCl2, 1 ×
GeneAmp PCR Gold buffer (Roche), 0.2 mM each dNTP,
200 ng of each oligonucleotide primer and ~500 ng
genomic DNA or 70 ng plasmid DNA template. After an
initial step at 94°C (15 min), 35 cycles of amplification
were performed (30 s at 94°C, 30 s at 59°C, 2 min at
72°C), followed by a final step at 72°C (10 min).
Western blots
This procedure was performed as previously described
[14]. Primary antibodies used were: anti-L1 ORF1 rabbit
polyclonal (1:500 dilution), anti-L1 ORF2 rabbit polyclo-
nal (1:200 dilution), anti-γ-H2AX rabbit polyclonal
(1:1000 dilution), or anti-γ-tubulin mouse monoclonal
(1:1000). HRP-conjugated secondary antibodies (Bio-
Rad) were used. The detection was performed using the
Immun-Star HRP Detection kit (Bio-Rad).
Immunofluorescence
This procedure was performed as described in Haoudi et
al [15]. Primary antibodies used were: anti-L1 ORF1 rab-
bit polyclonal (1:50 dilution), anti-L1 ORF2 rabbit poly-
clonal (1:100 dilution), anti-γ-H2AX rabbit polyclonal
(1:500 dilution). The secondary antibody Alex-Fluor anti-
rabbit (Molecular Probes) was used. The cells were viewed
using a Zeiss LSM510 confocal microscope outfitted with
Metamorph software. For quantitative analysis, foci were
counted by eye during the imaging process using a 63
objective. In a single experiment, cell counting was per-
formed until at least 40 cells and 40 foci were registered/
sample. For data points that were derived from a singleCancer Cell International 2006, 6:13 http://www.cancerci.com/content/6/1/13
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experiment, the error bars represent the SE from the anal-
ysis of the number of cells analyzed. For data points that
were derived from more than one experiment, the error
bars represent either the SE from the number of cells ana-
lyzed in the single experiments or the SE between the dif-
ferent experiments (whichever is highest).
Flow cytometry
This procedure was performed as previously described
[15]. To analyze the cell cycle profile, MCF-7 cells were
either mock transfected or transfected with GFP or RC-L1.
Forty eight hours later, RC-L1 transfected cells were sub-
jected to puromycin selection, then DNA flow analysis
was conducted on a BD Biosciences FACScan and ana-
lyzed with MODFIT software.
Caspase 3 assay
Caspase 3 assay was performed using BD ApoAlert Cas-
pase colorimetric assay kit following the manufacturer's
recommendations.
Gamma irradiation
T47D breast cancer cells were transfected with L1 plasmid
as described above. Cells were then irradiated with 5 Gy
using a 137Cesium source. Cells were returned to culture
then selected for puromycin resistance. Whole cell lysates
were then collected and subjected to immunoblotting
using anti-Bax antibody, as described above.
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